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Introduction
The Chromogranin A (CgA) is an acidic glycoprotein
member of the granin family, which was discovered
and described in 1960 [1-5]. This physiological protein
of MW 48 kDa [6-8] is produced and stored together
with biogenic amines and other peptide hormones in
the secretory granules called large dense-core vesicles
of the neuroendocrine cells [2,4-6,9,10], which are
widespread in the whole organism and form the dif-
fused endocrine system (DES) [11-13]. The neuroen-
docine cells can be found in: adrenal medulla, sympa-
thetic nerves endings, cerebral cortex, pituitary gland,
gastrointestinal tract, thyroid, parathyroid glands, pan-
creatic islets and lungs [2,4,8,10]. The synthesis and
secretion of CgA may be intensified in the neuroen-
docrine tumour (NET) cells [4,9,14,15]. 
CgA is secreted to the extracellular space, so it's
easily detectable in the blood [2,4,16]. Recent studies
confirmed that the measurement of CgA levels in
blood can also be used to diagnose and to monitor neu-
roendocrine tumours during treatment [6,10,14,16-18].
Neuroendocrine tumours are a rare and heteroge-
neous group of neoplasms characterized by embry-
ological, biological and histopathological differences.
Additional differences are related to either the pres-
ence or the absence of symptoms caused by endocrine
activity (biologically active or inactive NETs) or the
presence or absence of a somatostatin receptors
expressed on neuroendocrine tumour cells found in
scintigraphy [12,19-22]. Approximately 70% of all
cancers are neuroendocrine tumors of the gastrointesti-
nal tract called gastroenteropancreatic neuroendocrine
tumours (GEP-NET) [19,23]. In every case of diag-
nosed NET determination of CgA concentration has a
significant impact on the prognosis and the choice of
treatment and clinical outcome. Prognosis for the
patients with NET secreting CgA is better, having a
longer survival time and a prolonged time to progres-
sion [5,10,18,22,24,25]. 
The present study was performed in order to assess
the relationship between the concentration of CgA in
plasma and patients' selected clinical data (type of NET
according to the WHO classification, severity of disease
based on the presence of metastases and clinical symp-
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toms) and outcome of somatostatin receptor scintigraphy
(SRS). Moreover we evaluated the diagnostic power of
CgA determinations for the diagnosis of NET.
Materials and methods
A retrospective analysis of the results of the plasma CgA concen-
trations in relation to histopathological and clinical findings as well
as somatostatin receptor scintigraphy was performed in 41 patients
with NET. In most cases primary localisation was identified in the
gastrointestinal tract (73%) and lungs (15%). In individual cases
were ovarian cancers of unknown primary origin.
NET histological type was determined based on the WHO clas-
sification from 2000y. [26,27]:
1. WDNET well-differentiated neuroendocrine tumor
(benign or low grade malignant)
2. WDNEC well-differentiated neuroendocrine carcinoma
(low grade malignant)
3. PDNEC poorly-differentiated neuroendocrine carcinoma
(high grade malignant)
The patients were treated in The Oncological Centre of Lublin
Reguion from February 2005 to May 2008. The patients ages
ranged from 38 to 76 years (mean 58±10 years). The group includ-
ed 27 women (65,8%) and 14 men (34,2%), W/M index=1,9.
The control group was composed of healthy volunteers (n=15)
with age range from 23 to 53 years (mean age: 38±8 years). This
group included 10 women (60%) with the mean age of 41 years±9
and 5 men (40%) with the mean age 37±9 years, W/M index=2.
CgA determinations. Peripheral venous blood samples were col-
lected using standard veinpuncture technique. Volumes of 7 ml for
CgA determination were drawn into sterile tubes with EDTA as
anticoagulant and centrifuged within 1hr at 1000 rpm for 10 min.
All plasma samples were separated and aliquoted into eppendorfs
and stored at -20°C pending analysis. 
The CgA plasma determinations were performed with the use
of ELISA immunoenzymatic assay of commercially available kit
Chromogranin A (DakoCytomation, Denmark). Analyses were
done according to the manufacturer's instructions. During the
whole course of the study the kits from the same company were
used. Analytical sensitivity of the test was 2.0 U/l and imprecision
expressed as CV was 8.6%.
Statistical analysis. Plasma CgA concentrations in the studied
groups were reported with the use of descriptive statistic elements
(median Me, range or percentile (25-75%), minimum Min, maxi-
mum Max) as appropriate and the results are shown in the tables
and on the graphs. During statistical analysis the comparisons of
CgA concentrations between patients and control groups were per-
formed, as well as within the patients' group depending on the clin-
ical presentation of the disease. For statistical analysis of obtained
results, Statistica 7.0 StatSoft was used.
Distribution was tested for normality using Shapiro-Wilk W
test. Analysed parameters were found skew-distributed and there-
fore non parametric tests U Mann-Whitney and Kruskal-Wallis
were applied.
The cut-off value of 18 U/l was used according to the manufac-
turer's declaration. Sensitivity, specificity, positive and negative pre-
dictive values were calculated using the standard equations. Sensi-
tivity = true positive/true positive + false negative and specificity =
true negative/true negative + false positive. Positive predictive value
(PPV) = true positive/true positive + false positive and negative pre-
dictive value (NPV) = true negative/false negative + true negative.
In order to investigate the diagnostic value of plasma CgA we
plotted ROC (Receiver Operating Characteristic) curve and the
area under the curve (AUC) was calculated using Analyse-it
Microsoft Excel program. A p value ≤0.05 was considered as sta-
tistically significant in all analyses.
Results
In the plasma of NET patients with tumors CgA levels
were statistically significantly higher (p<0.001) com-
pared to the control group. The summary of CgA plas-
ma concentrations in the two groups are presented
below (Table 1 and Fig. 1).
Patients were subdivided into two groups, depend-
ing on the concentrations of plasma Cg A. 
Table 2 and 3 presents the results of plasma CgA and
evaluation of CgA in immunohistopathological
preparates in 41 patients with respect to clinical data
(type of tumor NET according to the WHO classifica-
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Table 1. Plasma levels of CgA [U/l] in the study and control group.
Fig. 1. Plasma levels of CgA [U/l] in the study and control group.
tion, severity of disease based on the presence of metas-
tases and clinical symptoms) and SRS results. Elevated
CgA in plasma was observed in 28 (68%) patients
(Table 1), whereas in 13 (32%) patients CgA levels fell
in reference ranges (Table 2). Immunocytochemical test
for the presence of GgA in the material collected from
the tumor site was positive in 97% of patients.
Table 4 and Fig. 2 summarises the plasma CgA
concentration results in patients depending on the
degree of neuroendocrine differentiation of NET.
Table 5 and Fig. 3 presents the codependence of plas-
ma CgA levels in the patients with the presence of dis-
tant metastases. 
Table 6 and Fig. 4 presents the patients plasma CgA
concentration results depending on the presence of
clinical symptoms. The predominant clinical symp-
toms of carcinoid were: flush, diarrhea, stomach con-
traction pain.
Compatibility between patients plasma CgA con-
centration and the results of SRS, were shown in Table
7. The compatibility between SRS and CgA determi-
nations in 27 patients who underwent somatostatin
receptor scintigraphy was 85%. 19 patients showed the
presence of somatostatin receptors and had elevated
plasma CgA, while 4 patients had negative SRS and
the normal concentration of CgA.
Assessment of CgA diagnostic power 
in neuroendocrine tumors (NET)
Diagnostic sensitivity and specificity of CgA in NET
and positive and negative predictive values for cut-off
value 18 U/l are 71%, 87%, 93%, 52% respectively.
Fig. 5 shows the ROC curve for CgA.
The area under the curve equal to 0.84 (p<0.0001)
indicates a good diagnostic usefulness of CgA in the
detection of NET.
Discussion
The secretory nature of NETs implies the determina-
tion of the CgA concentration as a standard marker.
The concentration of CgA in plasma correlates with
the degree of histopathological differentiation, tumor
stage, and is an essential prerequisite for therapy [5-7,
10,17,18,25,28]. Relating this study results of CgA
concentrations which were obtained over 3 years, to
histopathological and clinical parameters has led to
observations which have contributed to knowledge in
the field of NET diagnosis.
We demonstrated that in NET patients the median
value of CgA was significantly higher compared to
healthy people, which is consistent with reports of other
authors [10,14,20]. A comparison of plasma CgA results
with the results of CgA immunohistochemical staining
in the same patients (compiled in Table 2 and 3) clearly
indicates that low concentrations of CgA do not exclude
the presence of neuroendocrine tumor. The assessed
relationships between serum CgA in plasma and
histopathological tumor type showed that the concentra-
tion of plasma CgA was significantly higher in patients
with well differentiated NET compared with low grade
differentiation tumors. However in well differentiated
tumors low median value of CgA was observed.
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Table 2. NET patients with normal concentrations of CgA
Imm-hist-pat – immunohistopathological test; SRS – somatostasin receptors scintigraphy; LN – lymphatic nodules metastases; L – liver metastases; B –
bone metastases; P – lung metastases; C – CNS metastases; n/a – not available.
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Table 3. NET patients with elevated CgA concentration
Table 4. The concentration of plasma CgA of patients depending on the histopathological type of tumor (WHO classification)
p – level of statistical significance (p<0.05); * p level in comparison with WDNEC; ** p level in comparison with PDNEC
Imm-hist-pat – immunohistopathological test; SRS – somatostasin receptors scintigraphy; LN – lymphatic nodules metastases; L – liver metastases; B –
bone metastases; P – lung metastases; C – CNS metastases; n/a – not available.
According to the Seregni et al [28] and Stivanello
et al [29] the CgA plasma concentration in NET
patients reflects the differentiation grade of neuroen-
docrine tumor. Furthermore, Giovanella et al [7]
results indicate that a very high CgA concentration is 
a good prognostic marker and may indicate well-dif-
ferentiated neuroendocrine carcinomas. The author has
shown a correlation between the secretory granules
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Table 5. The concentration of plasma CgA in the patients' blood, depending on the presence or absence of distant metastases
p – level of statistical significance (p<0,05)
Table 6. The concentration of CgA in the blood plasma of patients, depending on the presence of clinical symptoms of carcinoid syn-
drome
p – level of statistical significance
Table 7. Compatibility between patients plasma CgA and the results of SRS
Pos- positive result     
Neg- negative result
Fig. 2. The concentration of plasma CgA in the patients depending
on the degree of NET differentiation.
* p level in comparison with WDNEC
** p level in comparison with PDNEC
Fig. 3. The concentration of plasma CgA of patients, depending on
the presence of distant metastases.
p – level of statistical significance
density in tumor cells and plasma CgA. Results of their
study showed that well-differentiated carcinomas are
characterized by numerous secretory vesicles and rela-
tively high plasma CgA, while low-differentiated
endocrine carcinomas contain fewer of secretory gran-
ules in the cells, and therefore are characterized by rela-
tively low CgA levels in plasma. Also, Rindi and Klöp-
pel [27] showed that CgA is usually absent or only
focally expressed in poorly differentiated neuroen-
docrine tumors because of the lost capacity of these
tumors to produce CgA. Our findings are in agreement
with above mentioned already published data.
In conducted retrospective analysis we demonstrat-
ed the relationship between serum CgA levels and the
presence of metastases. Elevated CgA was found in
95% of cases with distant metastases and only 38% of
cases without metastases. The highest concentrations
of CgA were observed in NET with liver metastases.
These relationships found confirmation in the
results obtained by Nehar et al [10]. In 124 GEP-NET
patients and 34 with MEN-1 (multiple endocrine neo-
plasma type 1) they demonstrated that the concentra-
tion of CgA correlates with the severity of disease
(p<0.001). Elevated levels of this marker were
observed in 73% of patients with metastases and in
26% of patients without metastases. These authors
noted that the percentage of elevated CgA results dif-
fered significantly (p<0.001) between patients with
metastases to regional lymph nodes (38%), liver metas-
tases (69%) and very advanced disease, with metas-
tases to the liver, lungs, bone and spleen (100%).
Similar results were obtained by Nobles et al [18]
and Peracchi et al [30] in their studies. Seregni et al
[28] and Sivanello et al [29] also demonstrated that the
CgA plasma concentration is elevated in patients with
tumors NET and strongly correlates with the severity
of the neoplastic process.
Baudin et al [17] and Tomassetti et al [22] suggest
that the CgA concentration in NET patients reflects the
spread of the tumor, with the highest values in the
presence of metastases in the liver, which is confirmed
by our results. Janson et al [24] found a correlation
between increasing levels of plasma CgA in patients
with carcinoid and the number of metastatic foci in the
liver. According to Campana et al [6] the concentration
of CgA of 282 U/l was the best cut-off value for diag-
nosis of patients with advanced neoplasm (sensitivity
71%, specificity 79%).
The high concentration of CgA may be a good
prognostic indicator for neuroendocrine cancer with a
high degree of differentiation, may also indicate the
presence of metastases as shown in our own observa-
tions and the outlined literature. Therefore, the results
of CgA should be closely interpreted with histopatho-
logical data and clinical patient phenotype.
A further subject of our study was to find relation-
ships between CgA plasma concentration and the pres-
ence of clinical symptoms of carcinoid. It has been
shown that the CgA plasma concentration is signifi-
cantly higher in patients with typical symptoms of car-
cinoid syndrome (flush, diarrhoea) compared with
patients with tumours endocrinally nonactive. Elevat-
ed plasma CgA was observed in all patients (100%)
with clinical symptoms and 56% of cases without any
symptoms. Our results are consistent with reports of
other authors [10,17,18,31].
According to Vinik A. [13] the plasma CgA con-
centrations in patients with GEP-NET may be depend-
ent on its secretory activity. CgA levels are signifi-
cantly elevated in the majority of GEP-NET, but the
highest values are observed in the classic carcinoid
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Fig. 4. The concentration of CgA in the blood plasma of patients,
depending on the presence of clinical symptoms of carcinoid syn-
drome.
Fig. 5. ROC curve for CgA
syndrome with metastasis, in which the concentration
of CgA may be increased from 100 to 1000 times.
Nehar et al [10] showed higher diagnostic sensitiv-
ity of CgA in hormonally active tumors than inactive
(73 vs. 45%, p<0.003). The percentage of elevated
CgA concentrations was greatest in patients with
secreting GEP-NET with metastases (78%) and lowest
(0%) with inactive tumors without metastases, as con-
firmed by our observations. Similar results were
obtained by Bajetta et al [14] and Nobles et al [18].
Moreover in the present study we assessed the rela-
tionship between the plasma CgA concentration in the
blood of NET patients and the presence of somato-
statin receptors. We obtained accordance of 85%
between the parameters. In a study conducted by Cim-
itan et al [31], this agreement was 75%.
The evaluation of the diagnostics power of CgA
ELISA determination in NET was the next subject of
the present study. We calculated diagnostic sensitivity
and specificity of CgA for the cut-off value 18 U/l pro-
posed by the manufacturer obtaining values of 71%
and 87% respectively. From other authors observations
the sensitivity of CgA as a marker of neuroendocrine
tumors of the gastrointestinal tract varies between 10-
100% with specificity of 68-100% [17,20]. Values of
CgA diagnostic sensitivity and specificity available in
the literature differ depending on the secretory activity
and the degree of tumor and also depend on the
method used to determine the concentration of CgA
and accepted cut-off value [5,6,10,17,25,32].
Campana et al [6] evaluated the diagnostic power
of CgA in the group of 238 NET patients localized in
the gastrointestinal tract and lungs, and 48 healthy sub-
jects. Using the same cut-off point (18 U/l) as in our
study, they received greater diagnostic sensitivity
(85%) and specificity (96%) for the diagnosis of NET.
With cut-off values from 17 to 34 U/l the estimated
value of the diagnostic sensitivity of CgA from 79 to
92% [30,33] and specificity from 83 to 91% [22,30,33]
was obtained in various other studies.
It is noteworthy that the concentration of CgA may
be distorted in patients treated with proton pump
inhibitors as demonstrated in previous reports [10].
Moreover increase in the false positive CgA concen-
trations can be observed in patients with chronic renal
failure, liver disease and gastric enterochromaffin-like
cell hyperplasia associated with hypergastrinemy [6,10]. 
Data from the literature and results of this study sug-
gest the use of CgA in the diagnosis and prognosis of
NET.
Conclusions
Analysis of this research results allows us to formulate
the following conclusions: 
1. Plasma CgA concentration analysed together with
histopathological assessment of tumor and the clin-
ical picture is a useful marker in the diagnosis of
neuroendocrine tumors.
2. Low plasma CgA concentrations do not exclude the
presence of neuroendocrine tumor.
3. High plasma CgA concentrations may indicate the
presence of highly-differentiated NET (WDNEC),
and also may indicate the presence of tumor metas-
tasis.
4. The highest CgA concentrations were observed in
patients with neuroendocrine tumors associated
with carcinoid symptoms and the presence of
metastases to the liver.
5. The DacoCytomation ELISA test for the determi-
nation of chromogranin A in plasma with the
accepted cutoff value of 18 U/l that was used in this
study has a good diagnostic power in detecting neu-
roendocrine tumors
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